Definitive Contract 75N93024C00047

This is a $295,116 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Acousticabio, Inc., a small business located in Cambridge, MA. The contract is for research and development of a hydrogel-based microparticle formation for the high-dose and sustained delivery of HIV-1 broadly neutralizing antibodies via subcutaneous injection. This award is related to NIAID's SBIR Solicitation PHS-2023-1, which includes topics on developing next-generation devices and materials-based platforms for administering HIV-1 broadly neutralizing antibodies, as well as other infectious disease and vaccine-related research areas. The contract has a firm fixed price pricing type and a completion date of July 31, 2025.